---
title: "Exact Sciences (EXAS.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/EXAS.US.md"
symbol: "EXAS.US"
name: "Exact Sciences"
industry: "Biotechnology"
datetime: "2026-05-20T03:03:48.833Z"
locales:
  - [en](https://longbridge.com/en/quote/EXAS.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/EXAS.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/EXAS.US.md)
---

# Exact Sciences (EXAS.US)

## Company Overview

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.51)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 17.69% |  |
| Net Profit YoY | 79.79% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 3246990000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -8.66% | D |
| Profit Margin | -6.40% | D |
| Gross Margin | 69.69% | A |
| Revenue YoY | 17.69% | B |
| Net Profit YoY | 79.79% | A |
| Total Assets YoY | -1.14% | D |
| Net Assets YoY | -0.05% | D |
| Cash Flow Margin | -236.33% | E |
| OCF YoY | 17.69% | B |
| Turnover | 0.55 | C |
| Gearing Ratio | 59.03% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Exact Sciences",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "17.69%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "79.79%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3246990000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-8.66%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-6.40%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "69.69%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "17.69%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "79.79%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.14%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-0.05%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-236.33%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "17.69%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.55",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "59.03%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -95.81 | 546/386 | - | - | - |
| PB | 8.30 | 377/386 | 8.18 | 5.28 | 4.12 |
| PS (TTM) | 6.14 | 129/386 | 6.22 | 4.28 | 3.47 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-05T05:00:00.000Z

Total Analysts: **22**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 5% |
| Overweight | 1 | 5% |
| Hold | 20 | 91% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 104.91 |
| Highest Target | 118.00 |
| Lowest Target | 105.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/EXAS.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/EXAS.US/norm.md)
- [Related News](https://longbridge.com/en/quote/EXAS.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/EXAS.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**